Introduction
The development of accurate and relatively simple methods for the analysis of bile acids in serum has led to studies seeking to relate qualitative and quantitative changes in serum bile acid patterns to specific diseases of the liver and biliary tree. Although the increased proportion of chenodeoxycholate in cirrhosis has been well documented [3] , the study of Sandberg [12] of normal infants and those with liver disease indicates that serum bile acid determinations are of limited usefulness in differential diagnosis.
The ability to distinguish reliably between extrahepatic biliary atresia and other cholestatic syndromes remains an unsolved clinical problem. Although the excretion of bile acids from the liver into the intestines is reduced in cholestasis [11] , it might be expected that there is less impairment in comparison to atresia. Based on this assumption, we have compared the changes in serum acid levels, before and after chole- International units, normal <15 IU. Normal = 1-2 /tg/ml. styramine therapy, in a group of infants with extrahepatic biliary atresia and other cholestatic syndromes.
Materials and Methods
Seven children are under study, some for as long as 2 years. Five of the children have been followed since birth and two entered the program at 2 years of age. None of the children were positive for hepatitis B virus, cytomegalo virus, or toxoplasmosis. a-1-Antitrypsin levels were normal. There was no evidence for galactosemia or tyrosinemia. All children underwent liver biopsy and six of the seven children had an exploratory laparotomy, verifying the diagnosis.
Gas-liquid chromatographic analysis of serum bile acids was done using the method previously reported [2] with minor modifications. Sample size was reduced from 5 to 0.5 ml serum. The internal standard was changed from 3a,Ga-dihydroxy-B-^-cholanoate to 3<x,-7 a ,12-keto-5-/?-cholanoate [18] . Acetate rather than trifluoroacetate derivatives were prepared because they can be stored for long periods of time without deterio- ration. Duplicate analyses of serum were done periodically and on these occasions the two values agree within 10%.
Other analytical studies were done either in the routine clinical laboratories of the various hospitals or by investigators who have been doing special studies as part of their research program [19] . Table I lists the seven children studied, all of whom presented a similar clinical picture in the neonatal period. The date and age of each child at the time of entry into the study corresponds to the serum bilirubin determination as well as to the initial serum bile acid (SBA) analysis. 5'-Nucleotidase determinations were consistently elevated in all children and wide fluctuations were observed, which appear unrelated to cholestyramine therapy. All of the children displayed a predominantly conjugated hyperbilirubinemia during the neonatal period which fell to levels of less than 2 mg/100 ml in one child before entry into the study. All had persistent elevations of bile acid levels in serum.
Results
Four patients (JJ, VC, MP, and ET) had predominantly chenodeoxycholate in plasma. This unexpected SBA pattern was initially observed in // who had been explored for jaundice at age 3 months and found to have extrahepatic biliary atresia. The initial SBA analysis at age 10 months showed 89% of the elevation to be in the chenodeoxycholate fraction. The infant was started on treatment with cholestyramine, 4 g/24 hr, at age 11 months and subsequent SBA determinations with respect to onset, duration, and dosage of cholestyramine therapy are given in Figure 1 . No fall in the total or component serum bile acid concentrations oc-curred, despite 9 months uninterrupted therapy. However, there has been a slow and gradual rise in the proportion of cholate from 11% to 56% of the total SBA over this period.
Subsequently, three additional neonates (VC, MP, and ET) with extrahepatic biliary atresia later confirmed by laparotomy, were found to display similar initial serum bile acid patterns and responses to cholestyramine (Table II) . The predominant bile acid was chenodeoxycholic acid. With short courses of cholestyramine (8-12 g/24 hr for 15-30 days), there was only a slight increase in the proportion of cholate to chenodeoxycholate, and some decrease of the total SBA in two of the three children (MP and ET). Fluid obtained from a dilated hilar duct proximal to the atretic segment in patient VC was found to contain chenodeoxycholate (298 jug/ml) but no cholate.
In three children (PL, KM, and JC) the initial serum bile acid pattern displayed predominantly cholic acid (Table I) . Patient KM was explored at age 3 months. Patent bile ducts were found and 0.3 ml bile was aspirated from the gallbladder and analyzed. The total hepatic bile acid concentration was 107 /xg/ml, of which 69% was cholic acid and 31% was chenodeoxycholic acid. The initial SBA determination at age 7 months revealed a total SBA of 218 pig/ml (Table I) of which 84% was cholic acid and 26% was chenodeoxycholic acid. Total SBA values fluctuated but did not begin to consistently fall until after cholestyramine, 12 g/24 hr, was started at age 10 months. During the initial treatment period, the ratio of cholate to chenodeoxycholate rose from 4 to 10 (Table III) , followed by a gradual, sustained reduction in the total SBA. Concomitantly, pruritis, which had been severe prior to cholestyramine therapy, disappeared, and the total bilirubin fell to 2 mg/100 ml.
Patient PL had been explored at age 2 months and diagnosed as having extrahepatic biliary atresia. He came to our attention at age 21 months, by which time jaundice, but not pruritis, had disappeared. Because of fluctuations in the serum bile acid levels, we began to study systematically the fasting and 2-hr postprandial levels (Fig. 2 , Table III ) and found that much of the fluctuation could be attributed to elevations after meals.
The following year, the serum cholesterol rose to 512 mg/100 ml and cholestyramine, 12 g/24 hr, treatment was started. Total bile acid levels both pre-and postprandial fell with a rise in the cholate-chenodeoxycholate level in serum from 4.0 to 12.0 (Fig. 2) . The serum cholesterol fell promptly to 230 mg/100 ml.
Patient JC was jaundiced at birth. Clinical and laboratory data, including liver biopsies at age 11 days and at age 2 years were interpreted as consistent with a cholestatic syndrome with no strong evidence for a diagnosis of extrahepatic biliary atresia. Exploratory laparotomy has not been done. At the time of entry into the study at age 27 months, the child was still jaundiced and had severe pruritus and hypercholesterolemia (>1500 mg/100 ml) with xanthoma. The total serum bile acid was 488 /xg/ml, 79% consisting of cholic acid. Cholestyramine therapy (Table III) was followed by a prompt fall in serum cholesterol to 400 mg/100 ml and bile acid levels to 83 jug/ml.
Discussion
Cholestatic syndromes presenting at any age are a difficult diagnostic and therapeutic problem. In the neonatal period, a major problem is the distinction between atresia of the extrahepatic bile ducts, and intrahepatic disturbances in bile formation. Among the intrahepatic disturbances that have been reported to occur are both anatomic reduction in the size of the bile secretory apparatus [1] and metabolic abnormalities in bile acid synthesis [10] . Because of the increased mortality rate associated with surgery [8] and the beneficial effect that can occur with cholestyramine therapy [13] , we undertook a study of the diagnostic and therapeutic usefulness of this agent.
The rationale for the use of cholestyramine as a diagnostic agent to distinguish between complete and incomplete interruption in bile flow is based on its capacity to bind bile salts in the intestines. No other mechanism of action for this nonabsorbable anion exchange resin has been established. As a consequence of binding there is an increase in fecal bile acid excretion and an increase in hepatic synthesis of bile acid.
Although cholestyramine can have a variety of effects on bowel motility which can cause problems [4] , no untoward effects occurred during the course of this study.
Depending on the relative rates of hepatic synthesis and fecal excretion of bile acids, pool size may remain the same or decrease. In addition to the effect of cholestyramine on bile acid turnover, it is known to increase the proportion of glycocholate present in the bile salt pool. This occurs because the resin is known to bind relatively more chenodeoxycholate compared with cholate [5, 7] and conjugation with glycine in the liver becomes proportionally greater when there is an increase in fecal excretion [6] . Thus, the effects of cholestyramine on bile acid metabolism are known and are predictable.
The administration of cholestyramine to infants with bile acid retention as part of a cholestatic syndrome can be expected to have an effect proportional to the amount of bile acid bound in the intestine. The sources of intestinal bile acids are primarily those excreted via the common bile duct by the liver, and to a minor extent, that derived from the turnover of intestinal mucosal cells that may contain bile salts absorbed from the extracellular fluid, when plasma levels are very high. Since the predominant source is via hepatic excretion, the effect of cholestyramine can be expected to be related for the most part to the amount of bile acid excreted via the bile ducts.
The three patients with a predominantly cholate pattern had a marked response to cholestyramine. Two of the babies (PL and JC) entered the study at about 2 years of age and had marked hypercholesterolemia. The serum cholesterol level fell more rapidly than the total serum bile acid level. During the course of these studies it became apparent that the serum bile acids fluctuate greatly during the day, presumably due to emptying of the gallbladder containing some bile salts. This view is supported by other studies in the adult [9] showing that individuals with elevated fasting levels of serum bile salts have three-to fourfold increases after eating. Consistent fasting samples are harder to obtain in babies on short interval feeding schedules, and probably also in young children.
For these reasons, we have placed more emphasis on following changes in the ratio of cholate to chenodeoxycholate as evidence of significant bile acid binding by cholestyramine. A cholate to chenodeoxycholate ratio which is initially greater than, or which more rapidly shifts to levels greater than 2 appears characteristic of the patients with a cholestatic syndrome and patent bile ducts. In patients seen later in life with hypercholesterolemia and high levels of cholate, a shift may be delayed in appearance. Although chenodeoxycholate is preferentially bound by the resin, it is present in relatively small amounts and, therefore, statistically, the resin will come in contact with much more cholate.
The four infants with predominantly chenodeoxycholate in the serum had much less of a response to cholestyramine. In three of the infants, the total serum bile acid level did not fall and only a slight increase in the proportion of cholate occurred after prolonged treatment. These relatively small changes are consistent with the view that small amounts of bile acids entering the intestinal lumen via the turnover of mucosal cells are bound by the resin.
One of the children (//) with a poor response to cholestyramine was known to have biliary atresia before treatment. The diagnosis of biliary atresia was strongly suspected preoperatively in the other three infants, based on the initial serum bile acid pattern and response to cholestyramine.
The predominance of chenodeoxycholate in babies subsequently found to have atresia was not anticipated. The studies by Sandberg [12] of serum bile acids in normal infants and in those with liver disease did not distinguish patterns particularly diagnostic of atresia or other specific diseases. Our experience thus far indicates that the appearance within the first few months of life of a predominantly chenodeoxycholate pattern is suggestive of extrahepatic atresia. Perhaps the mechanism for this occurrence is related to the more rapid development of cirrhosis in infants with complete atresia. The predominance of chenodeoxycholate in cirrhosis in the adult has previously been noted [3, 16] and has been found to be attributable to a marked reduction in the cholate pool [17] . In the light of present knowledge it seems most reasonable to consider the predominant chenodeoxycholate pattern as evidence of the cirrhosis that will occur in these infants [15] . One cannot exclude however, the speculative possibility that this pattern may have existed in fetal life and in some manner is related to the excretory defect.
Although it seems reasonable to attempt to distinguish extrahepatic atresia from other cholestatic syndromes, this latter group may represent a wide variety of undefined diseases affecting the liver. Thus, some may occur because of a paucity of intrahepatic bile ducts [13] and others because of the synthesis of excessive amounts of monohydroxy bile acids [10] , which are known to cause cholestasis [8] . Some infants apparently respond rapidly to intramuscular phenobarbital [14] and others have virtually no bile acid in their bile at the time of surgery [11] .
Of the seven children reported here, two appear to resemble those discussed previously [1] with marked hypercholesterolemia that responds rapidly to cholestyramine. Our findings in the other infants thus far do not permit any further classification. One baby, KM, failed to respond to phenobarbital therapy on two occasions, before cholestyramine therapy began. Thus, it seems likely that neonatal cholestatic syndromes represent a heterogeneous group of disorders that require long term study to fully characterize their course.
Summary
Seven children with persistent cholestatic syndromes have been followed for as long as 2 years. Serum bile acid levels were determined periodically before, during, and after treatment with cholestyramine. The initial serum bile acid pattern in four infants with extrahepatic biliary atresia showed predominantly chenodeoxycholic acid. Cholestyramine administration had relatively little effect on the total serum bile acid level and the ratio of cholate to chenodeoxycholate. Three infants with intrahepatic cholestatic syndromes had predominantly cholic acid in the serum and cholestyramine administration caused a reduction in the total level. The initial serum bile acid patterns and response to cholestyramine appears to distinguish between extrahepatic biliary atresia and other cholestatic syndromes.
